Prudential Financial Inc. Sells 4,989 Shares of Insulet Co. (NASDAQ:PODD)

Prudential Financial Inc. cut its holdings in Insulet Co. (NASDAQ:PODD - Free Report) by 12.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 36,219 shares of the medical instruments supplier's stock after selling 4,989 shares during the quarter. Prudential Financial Inc. owned about 0.05% of Insulet worth $9,433,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of PODD. SBI Securities Co. Ltd. acquired a new position in shares of Insulet in the fourth quarter valued at approximately $36,000. SRS Capital Advisors Inc. lifted its position in Insulet by 43.1% in the 4th quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier's stock valued at $49,000 after acquiring an additional 56 shares in the last quarter. Friedenthal Financial acquired a new position in Insulet in the 4th quarter worth $57,000. TD Private Client Wealth LLC increased its holdings in Insulet by 32.6% during the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier's stock worth $53,000 after purchasing an additional 56 shares in the last quarter. Finally, Assetmark Inc. raised its stake in shares of Insulet by 1,447.1% in the 4th quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier's stock valued at $69,000 after purchasing an additional 246 shares during the period.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on PODD. Wells Fargo & Company lifted their target price on Insulet from $305.00 to $322.00 and gave the company an "overweight" rating in a research report on Friday, February 21st. Raymond James reiterated an "outperform" rating and issued a $328.00 price objective (up from $294.00) on shares of Insulet in a report on Friday, February 21st. StockNews.com downgraded shares of Insulet from a "buy" rating to a "hold" rating in a research report on Tuesday, March 4th. Citigroup boosted their price target on shares of Insulet from $310.00 to $355.00 and gave the stock a "buy" rating in a research report on Friday, February 21st. Finally, Royal Bank of Canada assumed coverage on Insulet in a report on Thursday, March 6th. They issued an "outperform" rating and a $340.00 price objective for the company. Four investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to MarketBeat, Insulet has a consensus rating of "Moderate Buy" and an average target price of $292.06.

Remove Ads

Insider Transactions at Insulet

In other Insulet news, Director Wayne A.I. Frederick sold 1,825 shares of the stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total transaction of $501,875.00. Following the transaction, the director now owns 3,231 shares in the company, valued at $888,525. This represents a 36.10 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Eric Benjamin sold 12,394 shares of Insulet stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the sale, the executive vice president now owns 11,383 shares of the company's stock, valued at approximately $3,187,240. The trade was a 52.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.47% of the company's stock.

Insulet Stock Performance

Insulet stock traded down $12.33 during trading hours on Thursday, hitting $256.80. The company had a trading volume of 1,098,439 shares, compared to its average volume of 709,684. The firm has a 50-day moving average of $270.56 and a 200 day moving average of $259.45. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The firm has a market cap of $18.03 billion, a PE ratio of 44.35, a PEG ratio of 3.62 and a beta of 1.29. Insulet Co. has a one year low of $160.19 and a one year high of $289.46.

Insulet (NASDAQ:PODD - Get Free Report) last announced its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, topping analysts' consensus estimates of $1.00 by $0.15. The company had revenue of $597.50 million for the quarter, compared to analyst estimates of $582.02 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. On average, sell-side analysts expect that Insulet Co. will post 3.92 earnings per share for the current year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.